Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis

Journal of Clinical Investigation

Volumn 104, Issue 1, 1999, Pages 13-19

  Kuwano, Kazuyoshi ^a   Hagimoto, Naoki ^a   Kawasaki, Masayuki ^a   Yatomi, Takehiro ^b   Nakamura, Norio ^b   Nagata, Shigekazu ^c   Suda, Takashi ^d   Kunitake, Ritsuko ^a   Maeyama, Takashige ^a   Miyazaki, Hiroyuki ^a   Hara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b MOCHIDA PHARMACEUTICAL CO   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; FAS ANTIGEN; FAS LIGAND; MESSENGER RNA;

ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; LUNG FIBROSIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032717522     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5628     Document Type: Article

References (36)

1. Itoh, N., et al. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:233-243.
2. Suda, T., Takahashi, T., Golstein, T., and Nagata, S. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1169-1178.
3. Suda, T., et al. 1995. Expression of the Fas ligand in cells of T-cell-lineage. J. Immunol. 154:3806-3813.
4. Lowin, B., Hahne, M., Mattmenn, C., and Tschopp, J. 1994. Cytotoxic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 370:650-652.
5. Kägi, D., et al 1994. Fas and perforin pathways as major mechanisms of T-cell mediated cytotoxicity. Science. 265:528-530.
6. Dhein, J., Walczak, H., Bäumler, C., Debatin, K.M., and Krammer, P.H. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:438-441.
7. Brunner, T., et al. 1995. Cell-autonomous Fas(CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:441-444.
8. Ju, S.T., et al. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:444-448.
9. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., and Nagata, S. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:314-317.
10. Takahashi, T., et al. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969-976.
11. Ogasawara, J., et al. 1993. Lethal effect of the anti-Fas antibody in mice. Nature. 364:806-809.
12. Hiramatsu, N., et al. 1994. Immunohiscochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 19:1354-1359.
13. Polunovsky, V.A., et al. 1993. Role of mesenchymal cell death in lung remodeling after injury. J. Clin. Invest. 92:388-397.
14. Liebow, A. 1975. Definition and classification of interstitial pneumonia in human pathology. In Progress in respiration research. Volume 8. F. Baset and R. George, editors. S. Karger AG. Basel, Switzerland. New York, NY. 1-33.
15. Crystal, R.G., et al. 1984. Interstitial lung diseases of unknown cause. I. Disorders characterized by chronic inflammation of the lower respiratory tract. N. Engl. J. Med. 310:154-166.
16. Waf1/Cip1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 154:477-483.
17. Guinee, D., et al. 1996. Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. Am. J. Pathol. 149:531-538.
18. Bardales, R.H., Xie, S., Schaefer, R.F. and Hsu, S. 1996. Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury. Am. J. Pathol. 149:845-852.
19. Kuwano, K., et al. 1999. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am. J. Respir. Cell Mol. Biol. 20:53-60.
20. Harrison, J.H., Jr., Hoyt, D.G., and Lazo, J.S. 1989. Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice. Mol. Pharmacol. 36:231-238.
21. Omar, T., Geraldine, P., Belehradek, J., and Luis, M. 1993. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res. 53:5462-5469.
22. Margalet, V., Lucus, M., Solano, F., and Goberna, R. 1993. Sensitivity of insulin-secreting RIN m5F cells to undergoing apoptosis by the protein kinase C inhibitor Staurosporine. Exp. Cell Res. 209:160-163.
23. Hagimoto, N., Kuwano, K., Nomoto, Y., Kunitake, R., and Hara, N. 1997. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Cell Mol. Biol. 16:91-101.
24. Hagimoto, N., et al. 1997. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am. J. Respir. Cell Mol. Biol. 17:272-278.
25. Nagata, S., and Suda, T. 1995. Fas and Fas ligand: lpr and gld mutations. Immunol. Today. 16:39-43.
26. Suda, T., and Nagata, S. 1994. Purification and characterization of the Fas-ligand that induces apoptosis. J. Exp. Med. 179:873-879.
27. Miwa, K., et al. Caspase 1-dependent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4:1287-1292.
28. Woessner, J.F. 1961. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch. Biochem. Biophys. 93:440-447.
29. Takahashi, T., et al. 1994. Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 6:1567-1574.
30. Seino, K., Kayagaki, N., Okumura, K., and Yagita, H. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165-170.
31. Abreu-Martin, M.T., Vidrich, A., Lynch, D.H., and Targan, S.R. 1995. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen. J. Immunol. 155:4147-4154.
32. Roth, J.B., Murphy, E.D., and Eicher, E.M. 1984. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J. Exp. Med. 159:1-20.
33. Waldner, H., Sobel, R.A., Howard, E., and Kuchroo, V.K. 1997. Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159:3100-3103.
34. Sabelko, K.A., et al. 1997. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159:30396-3099.
35. Braun, M.Y., et al. 1996. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytotoxic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183:657-661.
36. Baker, M., Altman, N.H., Podack, E.R., and Levy, R.B. 1996. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183:2645-2656.